Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Stefan K. Barta"'
Autor:
Nadia Khan, Stefan K. Barta, Ying Yuan, Robin Joyce, Jason R. Westin, Sarah C. Rutherford, Silvia Senese, Jeremy S. Abramson, Nancy L. Bartlett, Trisha Ali-Shaw, John P. Leonard, Kami J. Maddocks
Publikováno v:
The Lancet Haematology. 8:e818-e827
Background Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) is a front-line treatment for patients with aggressive B-cell lymphomas. Bcl-2 is associated with chemoresistance due to BCL2 gene rea
Autor:
Cherie Tan, Lauren Shea, Yazeed Sawalha, Farrukh T. Awan, Geoffrey Shouse, Beth Christian, Tamara K. Moyo, Jonathon B. Cohen, Paolo Caimi, Qiuhong Zhao, Nishitha Reddy, Andrew R. Hsu, Murali Janakiram, Adam J. Olszewski, Joseph Maakaron, Natalie S Grover, Neil Palmisiano, Stefan K. Barta, Elvira Umyarova, Praveen Ramakrishnan Geethakumari, Kathryn G. Lindsey, Pallawi Torka, Alex F. Herrera, Kevin A. David, Celeste M. Bello, David M. Weiner, Ximena Jordan-Bruno, Narendranath Epperla, Nancy L. Bartlett, Michael C. Churnetski, Malathi Kandarpa, Sayan Mullick Chowdhury, Irl Brian Greenwell, Julia Sheets, Colin Thomas, Ryan A. Wilcox
Publikováno v:
Blood. 136:35-36
Introduction Ibrutinib was FDA approved for relapsed or refractory (R/R) marginal zone lymphoma (MZL) based on a phase II clinical trial that showed an overall response rate of 48% (Noy et al, Blood 2017). However, factors associated with response to
Autor:
Essel Dulaimi, Hongxing Sun, Lei-Zhen Zheng, Jean Pierre J. Issa, Yongnian Liu, Min Tao, Yi Zhang, Shan He, Henry C. Fung, Jian Wang, Ying Wang, Hanghang Zhang, Lijun Meng, Stefan K. Barta
Integrin αEβ7 (CD103) can interact with E-cadherin and promote T cell retention in epithelial tissue. However, whether the expression of CD103 on chimeric antigen receptor (CAR)-T cells may augment T cell anti-tumor activity remains unknown. Using
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a584c8d8e74e1d45445babf5544c9f7a
Autor:
Anas Younes, Stefan K. Barta, Connie Lee Batlevi, Tycel Phillips, Jason R. Westin, Sven de Vos, Krish Patel, John M. Pagel, Dena Grayson, Vikram Kansra, Sonali M. Smith, Jonathon B. Cohen
Publikováno v:
Journal of Clinical Oncology. 38:8056-8056
8056 Background: Fimepinostat (F), a dual inhibitor of PI3K (α, β, δ) and HDACs type 1/2, causes suppression of MYC levels (Shulman et al., 2017). A pooled analysis of diffuse large B-cell lymphoma (DLBCL) pts treated with F in two Ph 1/2 trials r
Autor:
Jason R. Westin, Nadia Khan, Sarah C. Rutherford, Silvia Senese, Kami J. Maddocks, Trisha Ali-Shaw, Robin Joyce, Nancy L. Bartlett, Stefan K. Barta, Ying Yuan, Jeremy S. Abramson, John P. Leonard
Publikováno v:
Journal of Clinical Oncology. 38:8003-8003
8003 Background: Dose-adjusted (DA) EPOCH-R is a frontline treatment for aggressive B-cell lymphomas. Bcl-2 is associated with chemoresistance due to BCL2 gene rearrangement or protein overexpression in lymphomas and is antagonized by BH3 mimetic ven
Autor:
Mitchell E. Hughes, Esin C. Namoglu, James N. Gerson, Sunita D. Nasta, Jakub Svoboda, Elise A. Chong, Daniel J. Landsburg, Stefan K. Barta, Stephen J. Schuster
Publikováno v:
Blood. 134:5261-5261
Introduction: Acalabrutinib (acala), a Bruton's Tyrosine Kinase inhibitor (BTKi), received accelerated FDA approval for treatment of mantle cell lymphoma (MCL) in 2017. Since approval, there has been limited "real world" data, especially in the setti
Autor:
John P. Plastaras, Mitchell E. Hughes, Stefan K. Barta, Carrie I Ho, W. Tris Arscott, Hatcher J. Ballard, Sunita D. Nasta, Jakub Svoboda, Abigail Doucette, Daniel J. Landsburg, Amit Maity, James N. Gerson, Stephen J. Schuster
Publikováno v:
Blood. 134:2905-2905
Introduction Novel agents such as ibrutinib, lenalidomide, and venetoclax are increasingly used in patients with relapsed/refractory lymphoma. A number of patients on these oral agents require radiation therapy (RT) either for palliation of their lym
Autor:
Sonali M. Smith, Kerry S. Campbell, Jasmine Zain, Richard I. Fisher, Daniel J. Landsburg, Stephen J. Schuster, Elise A. Chong, Carlyn Rose C. Tan, Henry C. Fung, Sunita D. Nasta, Jakub Svoboda, Nathan Fowler, Nadia Khan, Jia Ruan, Stefan K. Barta, James N. Gerson
Publikováno v:
Blood. 134:4031-4031
Background: Outcomes for relapsed or refractory mature T-cell lymphomas (RR TCL) are poor and have remained largely stagnant despite approval of several novel single agents in this setting over the last decade (Chihara D, et al. Br J Haematol. 2017).
Autor:
Daniel J. Landsburg, Alison W. Loren, Kyle W. Robinson, Emily C. Ayers, James N. Gerson, Edward A. Stadtmauer, Joanna Rhodes, Elise A. Chong, Esin C. Namoglu, Stephen J. Schuster, Mitchell E. Hughes, Stefan K. Barta, Sunita D. Nasta, Jakub Svoboda, Connie T. Suen
Publikováno v:
Blood. 134:5247-5247
Introduction: The type II anti-CD20 monoclonal antibody, obinutuzumab (OBI) is an effective therapy approved for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL). Data are limited for use of OBI as monoth
Autor:
Stefan K. Barta, Reinhard von Roemeling, Jason R. Westin, Connie Lee Batlevi, Daniel J. Landsburg, Sven de Vos, Tycel Phillips, Anas Younes, Sonali M. Smith, Krish Patel, Dena Grayson, Anna W. Ma, Jonathon B. Cohen, Zaw Win Myint
Publikováno v:
Blood. 134:4104-4104
Background High-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements (double- and triple-hit lymphoma), as well as diffuse large B-cell lymphoma (DLBCL), NOS with increased expression of MYC and BCL2 protein (double-expressor lym